Skip Nav Destination
“A fortuitous combination of circumstances”
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
Issue Archive
October 17 2013
In this Issue
Table of Contents
INSIDE BLOOD
CLINICAL TRIALS & OBSERVATIONS
“A fortuitous combination of circumstances”
Clinical Trials & Observations
BLOOD WORK
PLENARY PAPER
REVIEW ARTICLE
BLOOD CONSULT
CLINICAL TRIALS AND OBSERVATIONS
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Clinical Trials & Observations
Alessandra Larocca,Vittorio Montefusco,Sara Bringhen,Davide Rossi,Claudia Crippa,Roberto Mina,Monica Galli,Magda Marcatti,Giacinto La Verde,Nicola Giuliani,Valeria Magarotto,Tommasina Guglielmelli,Delia Rota-Scalabrini,Paola Omedé,Alberto Santagostino,Ileana Baldi,Angelo Michele Carella,Mario Boccadoro,Paolo Corradini,Antonio Palumbo
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
CME
Clinical Trials & Observations
Brief Report
Koichi Takahashi,Naveen Pemmaraju,Paolo Strati,Graciela Nogueras-Gonzalez,Jing Ning,Carlos Bueso-Ramos,Rajyalakshmi Luthra,Sherry Pierce,Jorge Cortes,Hagop Kantarjian,Guillermo Garcia-Manero
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies
Utthara Nayar,Pin Lu,Rebecca L. Goldstein,Jelena Vider,Gianna Ballon,Anna Rodina,Tony Taldone,Hediye Erdjument-Bromage,Max Chomet,Ronald Blasberg,Ari Melnick,Leandro Cerchietti,Gabriela Chiosis,Y. Lynn Wang,Ethel Cesarman
MYELOID NEOPLASIA
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Stephanie Beurlet,Nader Omidvar,Petra Gorombei,Patricia Krief,Carole Le Pogam,Niclas Setterblad,Pierre de la Grange,Christophe Leboeuf,Anne Janin,Maria-Elena Noguera,Florence Hervatin,Laure Sarda-Mantel,Marina Konopleva,Michael Andreeff,Andrea W. Tu,Alice C. Fan,Dean W. Felsher,Anthony Whetton,Marika Pla,Robert West,Pierre Fenaux,Christine Chomienne,Rose Ann Padua
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi,Michelle Maria Araujo Cruz,Nidhi Jyotsana,Amit Sharma,Haiyang Yun,Kerstin Görlich,Martin Wichmann,Adrian Schwarzer,Matthias Preller,Felicitas Thol,Johann Meyer,Reinhard Haemmerle,Eduard A. Struys,Erwin E. Jansen,Ute Modlich,Zhixiong Li,Laura M. Sly,Robert Geffers,Robert Lindner,Dietmar J. Manstein,Ulrich Lehmann,Jürgen Krauter,Arnold Ganser,Michael Heuser
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
VASCULAR BIOLOGY
Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin–restricted miRNA antagonists of miR-27
Jennifer A. Young,Ka Ka Ting,Jia Li,Thorleif Moller,Louise Dunn,Ying Lu,Angelina J. Lay,Joshua Moses,Leonel Prado-Lourenço,Levon M. Khachigian,Martin Ng,Philip A. Gregory,Gregory J. Goodall,Anna Tsykin,Ilana Lichtenstein,Christopher N. Hahn,Nham Tran,Nicholas Shackel,James G. Kench,Geoffrey McCaughan,Mathew A. Vadas,Jennifer R. Gamble
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Confocal microscopy of stained bone marrow cells showing subcellular localization of the RAS:BCL-2 complex shifting from the mitochondria in untreated acute myelogenous leukemic mice to the plasma membrane after treatment of the mice with ABT-737. The merged image shows the RAS:BCL-2 complex localizing in the plasma membrane. See the article by Beurlet et al on page 2864.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
